Filed by Pfizer Inc.
                           pursuant to Rule 425 under the Securities Act of 1933
                                           and deemed filed pursuant Rule 14a-12
                                          of the Securities Exchange Act of 1934
                                                   Commission File No: 001-02516
                                                Subject Company: Pharmacia Corp.

Article from Pfizer newsletter disseminated to Pfizer employees through its
internal intranet:

PFIZER, PHARMACIA TO RESPOND TO EC REQUEST FOR MORE INFORMATION

The European Commission (EC) -- the agency responsible for reviewing and
approving mergers and acquisitions in the European Union -- has asked Pfizer and
Pharmacia to provide additional information as part of the EC's ongoing review
of our proposed combination. According to Pfizer's Chief Financial Officer David
Shedlarz, who is leading the transition planning process, this is occasionally
done and is not particularly surprising given the size and complexity of our two
companies.

"We have been working collaboratively with the EC for several months," Shedlarz
says, "and we will quickly provide them with as much information as they need to
thoroughly review our proposal."

Shedlarz adds that the EC's request does not change Pfizer's expectation of when
the deal will close.

"What Hank said in his letter to colleagues last week, still holds true today,"
he says. "We continue to target closing the transaction by year-end 2002.
However, the final regulatory review process may result in the closing occurring
early in the first quarter of 2003."

                                      * * *

                              SAFE HARBOR STATEMENT

This release contains certain "forward-looking" statements within the meaning of
the Private Securities Litigation Reform Act of 1995. These statements are based
on management's current expectation and are naturally subject to uncertainty and
changes in circumstances. Actual results may vary materially from the
expectations contained herein. The forward-looking statements contained herein
include statements about future financial operating results and benefits of the
pending merger between Pfizer Inc. and Pharmacia Corp. Factors that could cause
actual results to differ materially from those described herein include: the
inability to obtain shareholder or regulatory approvals; actions of the U.S.,
foreign and local governments; the inability to successfully integrate the
businesses of Pfizer Inc. and Pharmacia Corp.; costs related to the merger; the
inability to achieve cost-cutting synergies resulting from the merger; changing
consumer or marketplace trends: and the general economic environment. Neither
Pfizer Inc. nor Pharmacia Corp. is under any obligation to (and expressly
disclaims any such obligation to) update or alter its forward-looking
statements, whether as a result of new information, future events, or otherwise.



Readers are also urged to carefully review and consider the disclosures in
Pfizer's and Pharmacia's various Securities and Exchange Commission ("SEC")
filings, including but not limited to Pfizer's and Pharmacia's Annual Reports on
Form 10-K for the year ended December 31, 2001, Pfizer's and Pharmacia's
Quarterly Reports on Form 10-Q for the quarterly period ended March 31, 2002,
and Pfizer's and Pharmacia's Quarterly Reports on Form 10-Q for the quarterly
period ended June 30, 2002.

On October 17, 2002, Pfizer filed an amended registration statement on Form S-4,
with the SEC. On October 22, 2002, Pfizer filed a joint proxy
statement/prospectus for Pfizer and Pharmacia, with the SEC. The joint proxy
statement/prospectus was first mailed to Pharmacia shareholders on or about
October 25, 2002. INVESTORS AND SECURITYHOLDERS ARE URGED TO READ THE
REGISTRATION STATEMENT, THE JOINT PROXY STATEMENT/PROSPECTUS AND ANY OTHER
RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC WHEN THEY BECOME
AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and
securityholders will be able to receive the joint proxy statement/prospectus and
other documents free of charge at the SEC's web site, www.sec.gov., Pfizer
securityholders will be able to receive the definitive version of the joint
proxy statement/prospectus and other documents free of charge by requesting them
in writing from Pfizer Inc., 235 East 42nd Street, New York, New York 10017,
Attention: Investor Relations, or by telephone: (212) 573-2688, and Pharmacia
securityholders will be able to receive the definitive version of the joint
proxy statement/prospectus and other documents free of charge by requesting them
in writing from Pharmacia Investor Relations at 100 Route 206 North, Peapack,
New Jersey 07977, or by telephone at (908) 901-8000.

Pfizer and Pharmacia and their respective directors and executive officers and
other members of management and employees may be deemed to be participants in
the solicitation of proxies in respect of the proposed transaction. Information
about the directors and executive officers of Pfizer and their ownership of
Pfizer shares is set forth in the proxy statement for Pfizer's 2002 annual
meeting of shareholders. Information regarding the interests of Pharmacia's
directors and executive officers in the proposed merger is set forth in the
definitive joint proxy statement/prospectus, filed on October 22, 2002, by
Pfizer that was first mailed to Pharmacia shareholders on or about October 25,
2002.